Rejuvenate Bio brings in $6 million for gene therapy work on age-related disease

Rejuvenate Bio has closed a $6 million financing round, adding new capital to a biotechnology company focused on gene therapies for age-related and chronic diseases. The financing was led by VCapital, according to the company’s announcement on June 8, 2026. Rejuvenate Bio did not specify a round label beyond calling it a financing round.

In one sentence, Rejuvenate Bio is building gene therapies aimed at the root causes of aging to treat chronic conditions affecting both companion animals and humans. That cross-species positioning is central to how the company presents itself. On its website, Rejuvenate Bio says advances in veterinary care are helping dogs live longer, which in turn has made chronic diseases such as osteoarthritis, heart disease, and cancer more important determinants of longevity and quality of life. It also points to the human burden of chronic disease, citing CDC data that six in ten Americans live with at least one chronic disease.

The $6 million raise gives Rejuvenate Bio more resources as it continues developing that pipeline. The company did not provide a detailed breakdown of how the proceeds will be used in the materials provided, but the funding comes as it advances its science and product pipeline around chronic, age-related disease.

The market context in Rejuvenate Bio’s own materials is clear: longer lifespans, in pets and people alike, are shifting attention toward diseases associated with aging. Rather than centering on a single condition in the information provided, the company is framing gene therapy as an approach that could address multiple chronic diseases tied to aging biology.

That makes this a broad platform story as much as a financing story. With VCapital leading the round, Rejuvenate Bio now has fresh backing for its effort to build gene therapies for diseases linked to aging across veterinary and human health.